Centrient Pharmaceuticals Netherlands B.V. Sustainability Profile
Centrient Pharmaceuticals Netherlands B.V., a leading player in the pharmaceutical industry, is headquartered in the Netherlands and operates across various regions globally. Founded in 2017, the company has quickly established itself as a key provider of essential medicines, particularly in the areas of antibiotics and anti-infectives. Centrient is renowned for its innovative approach to manufacturing and supplying high-quality active pharmaceutical ingredients (APIs) and finished dosage forms. Their commitment to sustainability and efficiency sets them apart in a competitive market. With a strong focus on meeting the needs of healthcare providers and patients, Centrient has achieved significant milestones, including expanding its product portfolio and enhancing its market presence. As a trusted partner in the healthcare sector, Centrient Pharmaceuticals continues to drive advancements in pharmaceutical solutions, reinforcing its position as a vital contributor to global health.
DitchCarbon Score
How does Centrient Pharmaceuticals Netherlands B.V.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Centrient Pharmaceuticals Netherlands B.V.'s score of 76 is higher than 85% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Centrient Pharmaceuticals Netherlands B.V.'s reported carbon emissions
In 2024, Centrient Pharmaceuticals Netherlands B.V. reported total carbon emissions of approximately 697.0 million kg CO2e. This figure includes Scope 1 emissions of about 142.9 million kg CO2e, Scope 2 emissions of approximately 118.1 million kg CO2e (market-based), and Scope 3 emissions totalling around 436.1 million kg CO2e. The previous year, 2023, saw total emissions of about 733.0 million kg CO2e, with Scope 1 at approximately 143.3 million kg CO2e, Scope 2 at about 141.4 million kg CO2e, and Scope 3 at around 448.2 million kg CO2e. Centrient Pharmaceuticals has not publicly disclosed specific reduction targets or initiatives as part of their climate commitments. The emissions data is cascaded from their parent company, Centrient Holding B.V., indicating a corporate family relationship that influences their sustainability reporting. Overall, Centrient Pharmaceuticals is actively monitoring its carbon footprint across all scopes, but further details on specific reduction strategies or commitments remain unspecified.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 121,708,000 | 000,000,000 | 00,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 242,430,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 |
How Carbon Intensive is Centrient Pharmaceuticals Netherlands B.V.'s Industry?
How Carbon Intensive is Centrient Pharmaceuticals Netherlands B.V.'s Location?
Centrient Pharmaceuticals Netherlands B.V.'s Scope 3 Categories Breakdown
Centrient Pharmaceuticals Netherlands B.V.'s Scope 3 emissions, which decreased by 3% last year and increased by approximately 22% since 2022, demonstrating supply chain emissions tracking. Most of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 63% of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 66% of Scope 3 emissions.
Top Scope 3 Categories
Centrient Pharmaceuticals Netherlands B.V.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Centrient Pharmaceuticals Netherlands B.V. has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
King-Friend Biochemical Pharmaceutical Co. Ltd.
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.